Navigation Links
Sweetpotato foundation seed tested in commercial operations
Date:7/1/2011

CHASE, LASweetpotato is gaining popularity in the United States, where health-conscious consumers have created increased demand for the tasty, versatile food. According to the U.S. Department of Agriculture, per capita consumption of the crop increased over 24% from 1998-2008 and the value of the U.S. sweetpotato crop in 2009 exceeded $400 million.

Production costs for sweetpotato crops are high, requiring that commercial growers optimize their production techniques and quality to keep up with consumer demand. Because sweetpotato is vegetatively propagated, viruses and mutations can accumulate readily, leading to plant decline. To maintain the integrity of commercial seed stock, sweetpotato foundation seed programs in the United States provide virus-tested foundation seed to commercial producers.

To better understand how rapidly the foundation seed declines after integration into commercial operations and to determine if production location affects decline, researchers conducted a study to evaluate changes in seed quality among farms in the major sweetpotato production areas of Louisiana. The results appeared in HortTechnology. "Although preliminary evaluations indicated that low incidence of re-infection with viruses can occur during the production of foundation seed, little information was available to evaluate how rapidly seed productivity and quality declined on farms, where older generations of sweetpotato are also grown and could serve as sources of inoculum for reinfection of new seed.", explained Christopher Clark, a Louisiana State University faculty member and lead author of the study.

G1 seed (seed grown 1 year after virus therapy in the foundation seed production field at the Sweet Potato Research Station, Louisiana State University Agricultural Center) was used as a reference to compare the yield and virus incidence of growers' generation 2 (G2) and generation 3 (G3) seed roots (grown in the growers' seed production fields 1or 2 years following the year of foundation seed production). "Although yields of plants grown from G2 and G3 seed were 86.3% and 86.1% for U.S. No. 1 and 83.3% and 86.0% for total marketable, respectively, compared with the yields from G1 seed, they were not significantly different", the scientists reported. Yield and virus incidence data suggested that seed quality may vary from year to year and from location to location.

Clark said that study results suggest that producers are indeed realizing yield benefits by incorporating virus-tested foundation seed into their production schemes. "It is also evident from the data that there is a decline in performance once this seed is increased on commercial farms in close proximity to older, infected propagating material. If the rate of virus re-infection on farms could be reduced, it appears that further improvements in yield could be realized", he added.

The scientists recommended that future studies should investigate methods that have proven useful on other crops, such as border crops, and the use of stylet oil sprays to reduce virus transmission. Additionally, clean seed programs should be augmented with enhanced virus resistance, tolerance, or both.


'/>"/>

Contact: Michael W. Neff
mwneff@ashs.org
703-836-4606
American Society for Horticultural Science
Source:Eurekalert  

Related biology news :

1. Guy Harvey Ocean Foundation funds University of Miamis R.J. Dunlap Program
2. Wildlife Conservation Society receives $150,000 grant from Newmans Own Foundation to save gorillas
3. Statement: The New York Stem Cell Foundation on lifting ban of federal funds for stem cell research
4. S.L.E. Lupus Foundation announces new grants to further NYC scientists leadership in lupus research
5. Michael S. Watson, Ph.D., receives Am College of Medical Genetics-ACMG Foundation Presidents Award
6. Fueling interventional radiology growth: SIR Foundation announces Navilyst Medical Pledge
7. ARVO Foundation for Eye Research honors Deisseroth with first Ludwig von Sallman Clinician-scientist Award
8. Anna-Kaisa Niemi awarded 2011 Genzyme/ American College of Medical Genetics Foundation Fellowship
9. Cystic Fibrosis Foundation funds Marshall research
10. Advertising Research Foundation Develops Standards for Neuromarketing Research
11. Philippine Foundation awarded grant for innovative bone health awareness program
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Sweetpotato foundation seed tested in commercial operations
(Date:5/16/2016)... 2016   EyeLock LLC , a market leader ... of an IoT Center of Excellence in ... development of embedded iris biometric applications. EyeLock,s ... and security with unmatched biometric accuracy, making it the ... DNA. EyeLock,s platform uses video technology to deliver a ...
(Date:4/28/2016)... , April 28, 2016 First quarter 2016: ... up 966% compared with the first quarter of 2015 ... SEK 589.1 M (loss: 18.8) and the operating margin was 40% ... 0.32) Cash flow from operations was SEK 249.9 M ... revenue guidance is unchanged, SEK 7,000-8,500 M. The operating ...
(Date:4/15/2016)... 15, 2016 Research and ... Biometrics Market 2016-2020,"  report to their offering.  , ... , ,The global gait biometrics market is expected ... the period 2016-2020. Gait analysis generates ... be used to compute factors that are not ...
Breaking Biology News(10 mins):
(Date:6/27/2016)... 2016  Global demand for enzymes is forecast ... to $7.2 billion.  This market includes enzymes used ... biofuel production, animal feed, and other markets) and ... Food and beverages will remain the largest market ... of products containing enzymes in developing regions.  These ...
(Date:6/27/2016)... Raleigh, NC (PRWEB) , ... June 27, 2016 ... ... a mission to bring innovative medical technologies, services and solutions to the healthcare ... development and implementation of various distribution, manufacturing, sales and marketing strategies that are ...
(Date:6/24/2016)... Epic Sciences unveiled a liquid biopsy ... PARP inhibitors by targeting homologous recombination deficiency (HRD) ... test has already been incorporated into numerous clinical ... Over 230 clinical trials are investigating ... PARP, ATM, ATR, DNA-PK and WEE-1. Drugs targeting ...
(Date:6/23/2016)... 2016   Boston Biomedical , an industry ... to target cancer stemness pathways, announced that its ... Drug Designation from the U.S. Food and Drug ... including gastroesophageal junction (GEJ) cancer. Napabucasin is an ... cancer stemness pathways by targeting STAT3, and is ...
Breaking Biology Technology: